Vanguard Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-2,972,383
| Closed | -$33.3M | – | 4137 |
|
|
2017
Q3 | $33.3M | Buy |
2,972,383
+15,012
| +0.5% | +$168K | ﹤0.01% | 2254 |
|
|
2017
Q2 | $32.5M | Buy |
2,957,371
+8,525
| +0.3% | +$93.8K | ﹤0.01% | 2236 |
|
|
2017
Q1 | $28.9M | Buy |
2,948,846
+248,785
| +9% | +$2.44M | ﹤0.01% | 2274 |
|
|
2016
Q4 | $29.2M | Buy |
2,700,061
+96,541
| +4% | +$1.04M | ﹤0.01% | 2234 |
|
|
2016
Q3 | $26.7M | Buy |
2,603,520
+162,448
| +7% | +$1.67M | ﹤0.01% | 2235 |
|
|
2016
Q2 | $31.9M | Buy |
2,441,072
+476,472
| +24% | +$6.22M | ﹤0.01% | 2113 |
|
|
2016
Q1 | $21.6M | Buy |
1,964,600
+172,564
| +10% | +$1.9M | ﹤0.01% | 2266 |
|
|
2015
Q4 | $16.5M | Buy |
1,792,036
+90,650
| +5% | +$834K | ﹤0.01% | 2390 |
|
|
2015
Q3 | $11.8M | Sell |
1,701,386
-292,410
| -15% | -$2.03M | ﹤0.01% | 2518 |
|
|
2015
Q2 | $19.6M | Buy |
1,993,796
+24,609
| +1% | +$242K | ﹤0.01% | 2366 |
|
|
2015
Q1 | $17.4M | Buy |
1,969,187
+154,824
| +9% | +$1.37M | ﹤0.01% | 2380 |
|
|
2014
Q4 | $15.9M | Buy |
1,814,363
+350,111
| +24% | +$3.07M | ﹤0.01% | 2344 |
|
|
2014
Q3 | $10.1M | Buy |
1,464,252
+6,284
| +0.4% | +$43.3K | ﹤0.01% | 2490 |
|
|
2014
Q2 | $7.67M | Buy |
1,457,968
+119
| +0% | +$626 | ﹤0.01% | 2641 |
|
|
2014
Q1 | $6.63M | Buy |
1,457,849
+69,195
| +5% | +$315K | ﹤0.01% | 2687 |
|
|
2013
Q4 | $7M | Buy |
1,388,654
+19,278
| +1% | +$97.2K | ﹤0.01% | 2622 |
|
|
2013
Q3 | $6.94M | Buy |
1,369,376
+29,857
| +2% | +$151K | ﹤0.01% | 2568 |
|
|
2013
Q2 | $6.64M | Buy |
+1,339,519
| New | +$6.64M | ﹤0.01% | 2516 |
|